Entrada Therapeutics

FDA rebuffs Entrada's attempt to get yearlong hold on DMD drug lifted
Fierce Biotech
Wed, 11/22/23 - 12:03 pm
Entrada Therapeutics
FDA
Duchenne Muscular Dystrophy
ENTR-601-44
Vertex flexes its dealmaking muscle
EP Vantage
Mon, 03/27/23 - 10:07 am
Vertex Pharmaceuticals
Entrada Therapeutics
Tevard Biosciences
Duchenne Muscular Dystrophy
Fresh from Vertex payday, Entrada's DMD plans are derailed by FDA hold
Fierce Biotech
Tue, 12/20/22 - 10:42 am
Entrada Therapeutics
Vertex Pharmaceuticals
FDA
clinical trials
Duchenne Muscular Dystrophy
myotonic muscular dystrophy
ENTR-601-44
Vertex pays Entrada $224M for preclinical rare disease drug, opening new front in assault on dystrophy
Fierce Biotech
Thu, 12/8/22 - 10:35 am
Vertex Pharmaceuticals
Entrada Therapeutics
ENTR-701
myotonic muscular dystrophy
IPO floodgates open up after summer lull as five more biotechs file for Nasdaq
Endpoints
Tue, 10/12/21 - 10:59 am
Evotec
Entrada Therapeutics
Aura Biosciences
Vaxxinity
Blue Water Vaccines
IPOs
Entrada raises $116M to take DMD therapy into the clinic
Fierce Biotech
Wed, 03/31/21 - 10:44 am
Entrada Therapeutics
Duchenne Muscular Dystrophy
Entrada Therapeutics Nabs $59M for Drugs that Gain “Entry” to Cells
Xconomy
Tue, 12/18/18 - 10:15 am
Entrada Therapeutics